Abstract
Adjuvant hormone therapy is considered the gold standard of therapy for hormone receptor-positive operable breast cancer. The approach to adjuvant hormone therapy in premenopausal patients has changed significantly in recent years. This change was caused by clinical trials, which have confirmed the advantage of adding ovarian suppression to tamoxifen or aromatase inhibitors monotherapy. Individual approach to choosing an appropriate regimen of adjuvant hormone therapy in premenopausal patients with breast cancer should be based on the assessment of risks for relapse, expected effectiveness of treatment and evaluation of drug safety.
Highlights
Individual approach to choosing an appropriate regimen of adjuvant hormone therapy in patients with early-stage breast cancer
Adjuvant hormone therapy is considered the gold standard of therapy for hormone receptor-positive operable breast cancer
The approach to adjuvant hormone therapy in premenopausal patients has changed significantly in recent years. This change was caused by clinical trials, which have confirmed the advantage of adding ovarian suppression to tamoxifen or aromatase inhibitors monotherapy
Summary
Адъювантная гормональная терапия является общепринятым стандартом лечения для женщин с гормоноположительным операбельным раком молочной железы. Индивидуальный подход к выбору адекватного объема адъювантной гормонотерапии у пациенток с раком молочной железы, находящихся в пременопаузальном периоде, должен осуществляться исходя из категорий риска развития рецидива заболевании, ожидаемой эффективности лечения и профиля безопасности препаратов. Для цитирования: Слонимская Е.М., Дорошенко А.В., Казанцева П.В. Индивидуальный подход к выбору варианта адъювантной гормональной терапии у пациенток с ранним раком молочной железы. Individual approach to choosing an appropriate regimen of adjuvant hormone therapy in premenopausal patients with breast cancer should be based on the assessment of risks for relapse, expected effectiveness of treatment and evaluation of drug safety. For citation: Slonimskaya E.M., Doroshenko A.V., Kazantseva P.V. et al Individual approach to choosing an appropriate regimen of adjuvant hormone therapy in patients with early-stage breast cancer. Рак молочной железы (РМЖ) – наиболее частое злокачественное заболевание у женщин в РФ. Согласно данным статистики, чаще у таких пациенток диагностируются люминальные, эстрогени/или прогестерон-рецептор-положительные опухоли (ER+, PR+), нередко характеризующиеся высокой
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
